Investment Thesis
Orchestra BioMed is a pre-commercial stage medical device company burning $22.2M annually on $110K revenue, indicating severe unit economics and no clear path to profitability. While the company maintains adequate liquidity ($28.4M cash) with reasonable leverage (0.36x Debt/Equity), current burn rate depletes cash reserves in approximately 1.3 years without significant revenue acceleration or cost reduction.
Strengths
- Strong liquidity position with 7.03x current ratio and $28.4M cash
- Controlled debt levels at 0.36x Debt/Equity ratio limiting financial distress risk
- Extreme revenue growth of 1169% YoY suggests early commercialization traction, though from minimal base
Risks
- Severe cash burn of $22.2M annually against $110K revenue demonstrates unsustainable unit economics
- Negative operating margin of -20069% and negative free cash flow indicates company is pre-profitability with no visibility to breakeven
- Limited cash runway of approximately 1.3 years at current burn rate without achieving significant revenue growth or cost controls
- Missing gross profit data suggests potential product or operational reporting issues
Key Metrics to Watch
- Quarterly revenue growth trajectory and achievement of $1M+ quarterly revenue milestone
- Operating cash burn rate and path to cash flow breakeven
- Gross margin visibility and achievement of positive contribution margins by product
Financial Metrics
Revenue
110.0K
Net Income
-20.7M
EPS (Diluted)
$-0.33
Free Cash Flow
-22.4M
Total Assets
100.7M
Cash
28.4M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-20,069.1%
Net Margin
-18,810.0%
ROE
-50.2%
ROA
-20.6%
FCF Margin
-20,320.0%
Balance Sheet & Liquidity
Current Ratio
7.03x
Quick Ratio
7.01x
Debt/Equity
0.36x
Debt/Assets
49.4%
Interest Coverage
-74.33x
Long-term Debt
15.0M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-13T09:00:22.702985 |
Data as of: 2026-03-31 |
Powered by Claude AI